Literature DB >> 2716347

Flow cytometric DNA analysis: a prognostic tool in non-Hodgkin's lymphoma.

B Christensson1, C Lindemalm, B Johansson, H Mellstedt, B Tribukait, P Biberfeld.   

Abstract

Surgical biopsies from 234 untreated patients with non-Hodgkin's lymphoma (NHL), classified according to the Kiel nomenclature, were analysed with respect to proliferative activity (S-phase) and DNA content by flow cytofluorometric (FCF-DNA) analysis. The percentage of cells in S-phase was significantly higher in lymphomas of high compared to low grade NHL (p less than 0.001). Patients with lymphomas of high grade histology and low S-phase values (less than 5.6%) achieved complete remission (CR) more often (p less than 0.05) and survived significantly longer than those with high S-phase values (p less than 0.05). In the low grade NHL group the S-phase value did not correlate to response. S-phase correlated to survival for patients with the lymphocytic (CLL & IC) (p less than 0.05) and follicle center cell (FCC) derived (p less than 0.01) but not in blastic (LB, IB, Burkitt) NHL. DNA-aneuploidy was associated with poor response to therapy and shorter CR duration in low grade NHL (p less than 0.05 for both). However, the degree of DNA-ploidy (neardiploid or aneuploid) did not correlate to survival in any of the NHL groups analysed (high- or low grade, lymphocytic, FCC derived or blastic). The Cox regression analysis indicated that the S-phase value was a stronger predictor of survival than histopathology, stage or age, especially in low grade NHL. These results suggest that S-phase analysis should be included in the clinical evaluation of NHL patients as a prognostic indicator.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2716347     DOI: 10.1016/0145-2126(89)90067-2

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  Tanzanian malignant lymphomas: WHO classification, presentation, ploidy, proliferation and HIV/EBV association.

Authors:  Amos R Mwakigonja; Ephata E Kaaya; Thomas Heiden; German Wannhoff; Juan Castro; Fatemeh Pak; Anna Porwit; Peter Biberfeld
Journal:  BMC Cancer       Date:  2010-07-01       Impact factor: 4.430

2.  Proliferating cell nuclear antigen (PCNA) as a prognostic factor in non-Hodgkin's lymphoma.

Authors:  P J Klemi; K Alanen; S Jalkanen; H Joensuu
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

3.  Tumour cell proliferation, but not apoptosis, predicts survival in B-cell non-Hodgkin's lymphomas.

Authors:  T Stokke; E B Smeland; S Kvaløy; H Holte
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

4.  Proliferation and apoptosis in malignant and normal cells in B-cell non-Hodgkin's lymphomas.

Authors:  T Stokke; H Holte; L Smedshammer; E B Smeland; O Kaalhus; H B Steen
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.